Anavex Life Sciences Corp. (NASDAQ:AVXL) shares traded down 4.1% during trading on Friday . The stock traded as low as $3.00 and last traded at $3.01, with a volume of 609,793 shares traded. The stock had previously closed at $3.14.

Several research analysts have recently commented on the stock. Zacks Investment Research cut shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Maxim Group set a $15.00 target price on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a report on Wednesday, July 27th. Finally, FBR & Co reiterated an “outperform” rating and set a $10.00 price target on shares of Anavex Life Sciences Corp. in a research report on Tuesday, July 26th.

The stock has a 50 day moving average of $4.76 and a 200-day moving average of $4.77. The stock’s market cap is $108.56 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. Equities research analysts forecast that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.